Petersen Rebecca Ann 4
4 · CapsoVision, Inc · Filed Aug 22, 2025
Insider Transaction Report
Form 4
Petersen Rebecca Ann
Director of Clinical Affairs
Transactions
- Exercise/Conversion
Common Stock
2025-08-18$0.37/sh+24,834$9,097→ 24,834 total - Exercise/Conversion
Stock Option (right to buy)
2025-08-18−7,507→ 0 totalExercise: $0.37Exp: 2031-10-31→ Common Stock (7,507 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-08-18−17,327→ 3,694 totalExercise: $0.37Exp: 2032-03-22→ Common Stock (17,327 underlying)
Footnotes (4)
- [F1]These options were previously reported at exercise price of $0.11 per share. The exercise price reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.
- [F2]The option was granted on October 28, 2021 and is fully vested and exercisable as of the transaction date.
- [F3]There options were previously reported as covering 25,000 and 70,000 shares, respectively. The number of shares reported herein gives effect to a 1-for-3.33 reverse stock split effected by the Issuer on July 2, 2025 in connection with its initial public offering.
- [F4]The option was granted on March 23, 2022 and is partially vested and exercisable as of the transaction date.